Obesity, particularly intra-abdominal (visceral) obesity, is a leading cause of cardiovascular disease (CVD), insulin resistance, type 2 diabetes, dyslipidaemia, inflammation and thrombosis. A useful indicator for visceral fat is waist circumference, which is associated with all-cause mortality. Pro-inflammatory adipokines play a causal role in the development of pathologies associated with insulin resistance, type 2 diabetes and CVD. In addition to established anti-obesity therapies, namely orlistat and sibutramine, a new type of agent that inhibits the cannabinoid receptor (CB1) is advanced in development to reduce appetite and act predominantly against intra-abdominal adiposity.
York DA, Rossner S., Caterson I. et al. Obesity, a worldwide epidemic related to heart disease and stroke group I: worldwide demographics of obesity. Circulation2004;110:e463-70.
2.
Emery EM, Schmid TL, Kahn HS et al. A review of the association between abdominal fat distribution, health outcome measures, and modifiable risk factors. Am J Health Promot1993;7:342-53.
3.
Despres JP, Lemieux I., Prud'homme D.Treatment of obesity: need to focus on high risk abdominally obese patients . BMJ2001;322:716-20.
Stumvoll M., Goldstein BJ, van Haeften TWType 2 diabetes: principles of pathogenesis and therapy. Lancet2005;365:1333-46.
6.
International Diabetes Federation.The IDF worldwide definition of the metabolic syndrome. Launched 14 April 2005. Accessible via http://www.idf.org/home/index.cfm?unode=32EF2063-B966-468F-928C-A5682A4E3910(accessedSept2005).
7.
Alberti KG, Zimmet P., Shaw J.; IDF Epidemiology TaskForce Consensus Group.The metabolic syndrome - a new worldwide definition. Lancet2005;366:1059-62.
8.
Reaven GMThe metabolic syndrome: requiescat in pace. Clin Chem2005;51:931-8.
Klein S.The case of visceral fat: argument for the defense. J Clin Invest2004;113:1530-2.
11.
Pouliot MC, Despres JP, Lemieux S. et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol1994;73:460-8.
12.
Bigaard J., Frederiksen K., Tjonneland A. et al. Waist and hip circumferences and all-cause mortality: usefulness of the waist-to-hip ratio?Int J Obes Relat Metab Disord2004;28:741-7.
13.
Kannel WB, Cupples LA, Ramaswami R. et al. Regional obesity and risk of cardiovascular disease: the Framingham Study. J Clin Epidemiol1991;44:183-90.
14.
Yusuf S., Hawken S., Ounpuu S. et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet2004;364:937-52.
15.
Ritchie SA, Ewart MA, Perry CG et al. The role of insulin and the adipocytokines in regulation of vascular endothelial function. Clin Sci (Lond)2004;107:519-32.
16.
Perry C., Sattar N., Petrie J.Adipose tissue : passive sumper active pump. Br J Diabetes Vasc Dis2001;1:110-14.
17.
Lau DC, Dhillon B., Yan H. et al. Adipokines: molecular links between obesity and atherosclerosis . Am J Physiol Heart Circ Physiol2005;288: H2031-41.
18.
Arner P.Insulin resistance in Type 2 diabetes - role of the adipokines. Curr Mol Med2005;5:333-9.
19.
Wajchenberg BLSubcutaneous and visceral adipose tissue: theirrelation to the metabolic syndrome. Endocr Rev2000;21:697-738.
20.
Fasshauer M. , Paschke R.Regulation of adipocytokines and insulin resistance . Diabetologia2003;46:1594-603.
21.
Trayhurn P.The biology of obesity. Proc Nutr Soc2005;64:31-8.
22.
Hansson GKInflammation, atherosclerosis, and coronary artery disease. NEJM2005;352:1685-95.
23.
3. Stewart KJ, Bacher AC, Turner K. et al. Exercise and risk factors associated with metabolic syndrome in older adults. Am J Prev Med2005;28:918.
24.
McAuley KA, Hopkins CM, Smith KJ et al. Comparison of high-fat and high-protein diets with a high-carbohydrate diet in insulin-resistant obese women. Diabetologia2005;48:8-16.
25.
Pirozzo S., Summerbell C., Cameron C. et al. Advice on low-fat diets for obesity. Cochrane Database Syst Rev2002;2:CD003640.
26.
Norris SL, Zhang X., Avenell A. et al. Long-term non-pharmacologic weight loss interventions for adults with Type 2 diabetes. Cochrane Database Syst Rev2005;2:CD004095.
27.
Pagotto U., Pasquali R.Fighting obesity and associated risk factors by antagonising cannabinoid Type 1 receptors. Lancet2005;365:1363-4.
28.
National Obesity Forum (NOF) Guidelines: Appendix 2 - Accessible via www.nationalobesityforum.org.uk (accessed Sept 2005 ).
29.
NICE Technology Appraisal Guidance - No. 22: Guidance on the use of orlistat for the treatment of obesity in adults. March 2001.
30.
NICE Technology Appraisal Guidance - No. 31: Guidance on the use of sibutramine for the treatment of obesity in adults. October 2001.
31.
Bailey CJ, Day C.New pharmacological approaches to obesity. Obesity in Practice2005;1:2-5.
32.
Sjostrom L. , Rissanen A., Andersen T. et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet1998;352:167-72.
James WP, Astrup A., Finer N. et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group.Sibutramine Trial of Obesity Reduction and Maintenance. Lancet2000;356:2119-25.
35.
Finer N., Pagotto U.The endocannabinoid system: a new therapeutic target for cardiovascular risk factor management. Br J Diabet Vasc Dis2005 ;5:121-4.
36.
Di Marzo V. , Goparaju SK, Wang L. et al.Leptin-regulated endocannabi-noids are involved in maintaining food intake. Nature2001;410:822-5.
37.
Bensaid M., Gary-Bobo M., Esclangon A. et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol2003;63:908-14.
38.
Rinaldi-Carmona M., Barth F., Heaulme M. et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett1994;350:240-4.
39.
Ravinet Trillou C., Arnone M., Delgorge C. et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol2003;284:R345-53.
40.
Cota D., Marsicano G., Tschop M. et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest2003;112:423-31.
41.
Ravinet Trillou C., Delgorge C., Menet C. et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord2004; 28:640-8.
42.
Poirier B., Bidouard JP, Cadrouvele C. et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab2005;7:65-72.
43.
Van Gaal LF , Rissanen AM, Scheen AJ et al. RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet2005;365:1389-97.
44.
Pi-Sunyer FXEffect of rimonabant on weight reduction and weight maintenance: RIO North America (RIO-NA) trial. Circulation2005; 111:1727.
